Allocation to matched-related or unrelated donor results in similar clinical outcomes without increased risk of failure to proceed to transplant among patients with acute myeloid leukemia: a retrospective analysis from the time of transplant approval

Acute myeloid leukemia (AML) represents the most common indication for allogeneic hematopoietic stem cell transplantation (allo-SCT) worldwide1. Despite major progresses in our understanding of AML biology and the recent arrival of emerging targeted therapies to the field, allo-SCT remains the first-choice consolidation strategy for fit patients in first remission who are at a high risk of relapse2,3,4. Moreover, allo-SCT is the only therapeutic option resulting in significant long-term survival rates in patients with refractory or relapsed disease5.

Source: Biology of Blood and Marrow Transplantation - August 25, 2018 Category: Hematology Authors: Eduardo Rodr íguez-Arbolí, Francisco José Márquez-Malaver, Nancy Rodríguez-Torres, Teresa Caballero-Velázquez, Virginia Escamilla-Gómez, Cristina Calderón-Cabrera, José Francisco Falantes-González, María Solé-Rodríguez, Patricia García-Ramí Source Type: research